AU2012347397B2 - 6-difluoromethyl-5,6-dihydro-2H-[1,4]oxazin-3-amine derivatives - Google Patents

6-difluoromethyl-5,6-dihydro-2H-[1,4]oxazin-3-amine derivatives Download PDF

Info

Publication number
AU2012347397B2
AU2012347397B2 AU2012347397A AU2012347397A AU2012347397B2 AU 2012347397 B2 AU2012347397 B2 AU 2012347397B2 AU 2012347397 A AU2012347397 A AU 2012347397A AU 2012347397 A AU2012347397 A AU 2012347397A AU 2012347397 B2 AU2012347397 B2 AU 2012347397B2
Authority
AU
Australia
Prior art keywords
dementia
compound
acid
disease
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012347397A
Other languages
English (en)
Other versions
AU2012347397A1 (en
Inventor
Henricus Jacobus Maria Gijsen
Hana Prokopcova
Michel Surkyn
Andres Avelino Trabanco-Suarez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2012347397A1 publication Critical patent/AU2012347397A1/en
Application granted granted Critical
Publication of AU2012347397B2 publication Critical patent/AU2012347397B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2012347397A 2011-12-05 2012-12-04 6-difluoromethyl-5,6-dihydro-2H-[1,4]oxazin-3-amine derivatives Ceased AU2012347397B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11191997.3 2011-12-05
EP11191997 2011-12-05
PCT/EP2012/074351 WO2013083557A1 (en) 2011-12-05 2012-12-04 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives

Publications (2)

Publication Number Publication Date
AU2012347397A1 AU2012347397A1 (en) 2014-04-24
AU2012347397B2 true AU2012347397B2 (en) 2016-09-22

Family

ID=47278317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012347397A Ceased AU2012347397B2 (en) 2011-12-05 2012-12-04 6-difluoromethyl-5,6-dihydro-2H-[1,4]oxazin-3-amine derivatives

Country Status (18)

Country Link
US (1) US20140343048A1 (enExample)
EP (1) EP2788346B1 (enExample)
JP (1) JP6169095B2 (enExample)
KR (1) KR102060379B1 (enExample)
CN (1) CN103974951B (enExample)
AU (1) AU2012347397B2 (enExample)
BR (1) BR112014013310A2 (enExample)
CA (1) CA2852366C (enExample)
EA (1) EA023909B1 (enExample)
ES (1) ES2558604T3 (enExample)
IL (1) IL232916A (enExample)
MX (1) MX357384B (enExample)
MY (1) MY165209A (enExample)
PH (1) PH12014501235B1 (enExample)
SG (1) SG11201402734XA (enExample)
UA (1) UA111749C2 (enExample)
WO (1) WO2013083557A1 (enExample)
ZA (1) ZA201404074B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151098A1 (ja) 2008-06-13 2009-12-17 塩野義製薬株式会社 βセクレターゼ阻害作用を有する含硫黄複素環誘導体
UA110467C2 (uk) 2009-12-11 2016-01-12 Шионогі Енд Ко., Лтд. Похідні оксазину
AU2011263797B2 (en) 2010-06-09 2014-06-05 Janssen Pharmaceutica Nv 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE)
JP5834091B2 (ja) 2010-12-22 2015-12-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ ベータ−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な５，６−ジヒドロ−イミダゾ［１，２−ａ］ピラジン−８−イルアミン誘導体
JP5853035B2 (ja) 2011-03-09 2016-02-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な３，４−ジヒドロ−ピロロ［１，２−ａ］ピラジン−１−イルアミン誘導体
US20140364428A1 (en) * 2011-12-06 2014-12-11 Janssen Pharmaceutica Nv 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
CA2912156C (en) 2013-06-12 2021-07-20 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace)
CA2911693C (en) 2013-06-12 2021-08-24 Janssen Pharmaceutica Nv 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
AU2014280124B2 (en) 2013-06-12 2018-11-01 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (BACE)
CA2967164A1 (en) 2014-12-18 2016-06-23 Janssen Pharmaceutica Nv 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase
US20230074641A1 (en) * 2020-01-27 2023-03-09 Silcotek Corp. Biopharmaceutical manufacturing process and product

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011009943A1 (en) * 2009-07-24 2011-01-27 Novartis Ag Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders
WO2011020806A1 (en) * 2009-08-19 2011-02-24 F. Hoffmann-La Roche Ag 3-amino-5-phenyl-5,6-dihydro-2h-[1,4]oxazine derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103272C2 (uk) * 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
AU2011263797B2 (en) * 2010-06-09 2014-06-05 Janssen Pharmaceutica Nv 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE)
EA201391029A1 (ru) * 2011-01-12 2014-01-30 Новартис Аг Производные оксазина и их применение при лечении неврологических нарушений
WO2012147763A1 (ja) * 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
US20140364428A1 (en) * 2011-12-06 2014-12-11 Janssen Pharmaceutica Nv 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011009943A1 (en) * 2009-07-24 2011-01-27 Novartis Ag Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders
WO2011020806A1 (en) * 2009-08-19 2011-02-24 F. Hoffmann-La Roche Ag 3-amino-5-phenyl-5,6-dihydro-2h-[1,4]oxazine derivatives

Also Published As

Publication number Publication date
EP2788346A1 (en) 2014-10-15
WO2013083557A1 (en) 2013-06-13
PH12014501235A1 (en) 2014-09-08
MX2014006689A (es) 2014-09-04
BR112014013310A2 (pt) 2017-06-13
JP2015500223A (ja) 2015-01-05
UA111749C2 (uk) 2016-06-10
MY165209A (en) 2018-03-05
MX357384B (es) 2018-07-06
EA201491116A1 (ru) 2014-12-30
NZ626662A (en) 2015-05-29
EA023909B1 (ru) 2016-07-29
IL232916A (en) 2016-07-31
IL232916A0 (en) 2014-08-03
KR102060379B1 (ko) 2019-12-30
JP6169095B2 (ja) 2017-07-26
EP2788346B1 (en) 2015-10-28
ES2558604T3 (es) 2016-02-05
AU2012347397A1 (en) 2014-04-24
PH12014501235B1 (en) 2014-09-08
KR20140107209A (ko) 2014-09-04
ZA201404074B (en) 2016-10-26
US20140343048A1 (en) 2014-11-20
CN103974951B (zh) 2016-04-13
CN103974951A (zh) 2014-08-06
CA2852366A1 (en) 2013-06-13
SG11201402734XA (en) 2014-06-27
CA2852366C (en) 2020-02-18
HK1198586A1 (zh) 2015-04-30

Similar Documents

Publication Publication Date Title
CA2852366C (en) 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
AU2012224632B2 (en) 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
EP2588466B1 (en) 5-Amino-3,6-dihydro-1H-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (BACE)
JP5711813B2 (ja) βセクレターゼ（ＢＡＣＥ）の阻害剤として有用な５，６−ジヒドロ−２Ｈ−［１，４］オキサジン−３−イル−アミン誘導体
AU2012347396B2 (en) 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2H-[1,4]oxazin-3-amine derivatives
WO2012117027A1 (en) 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace)
WO2012000933A1 (en) 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
WO2012085038A1 (en) 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
NZ626662B2 (en) 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
HK1198586B (zh) 6-二氟甲基-5，6-二氢-2h-[1，4]恶嗪-3-胺衍生物
AU2011263836A1 (en) 5-amino-3,6-dihydro-1H-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (BACE)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired